Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878–1890 (2023).
Agrawal, M. et al. Changing epidemiology of immune-mediated inflammatory diseases in immigrants: a systematic review of population-based studies. J. Autoimmun. 105, 102303 (2019).
Article PubMed PubMed Central Google Scholar
Conrad, N. et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400, 733–743 (2022).
Tyndall, A. J. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 69, 1809–1815 (2010).
Libby, P. & Weyand, C. Immune and inflammatory mechanisms mediate cardiovascular diseases from head to toe. Cardiovasc. Res. 117, 2503–2505 (2021).
CAS PubMed PubMed Central Google Scholar
Tschöpe, C., Cooper, L. T., Torre-Amione, G. & Van Linthout, S. Management of myocarditis-related cardiomyopathy in adults. Circ. Res. 124, 1568–1583 (2019).
Goodson, N. J. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 52, 2293–2299 (2005).
Article CAS PubMed Google Scholar
Solomon, D. H. et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 67, 1449–1455 (2015).
Article CAS PubMed PubMed Central Google Scholar
Arts, E. E. A., Fransen, J., Den Broeder, A. A., Van Riel, P. L. C. M. & Popa, C. D. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann. Rheum. Dis. 76, 1693–1699 (2017).
Article CAS PubMed Google Scholar
Myasoedova, E. et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann. Rheum. Dis. 75, 560–565 (2016).
Article CAS PubMed Google Scholar
Provan, S. A. et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann. Rheum. Dis. 70, 812–817 (2011).
Crowson, C. S. et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann. Rheum. Dis. 77, 48–54 (2018).
Article CAS PubMed Google Scholar
Roy, P., Orecchioni, M. & Ley, K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. 22, 251–265 (2022).
Article CAS PubMed Google Scholar
Mallat, Z. & Binder, C. J. The why and how of adaptive immune responses in ischemic cardiovascular disease. Nat. Cardiovasc. Res. 1, 431–444 (2022).
Article PubMed PubMed Central Google Scholar
Panahi, M. et al. Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. Cardiovasc. Res. 114, 1445–1461 (2018).
Article CAS PubMed PubMed Central Google Scholar
Sarwar, N. et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012).
IL6R MR Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 379, 1214–1224 (2012).
Weber, B. N., Giles, J. T. & Liao, K. P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat. Rev. Rheumatol. 19, 417–428 (2023).
Article PubMed PubMed Central Google Scholar
Choy, E. H. et al. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335–345 (2020).
Article CAS PubMed PubMed Central Google Scholar
Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).
Article CAS PubMed Google Scholar
Akita, K., Isoda, K., Sato-okabayashi, Y., Kadoguchi, T. & Kitamura, K. An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice. Front. Cardiovasc. Med. 4, 84 (2017).
Article PubMed PubMed Central Google Scholar
Cai, T. et al. Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy a phenome-wide association study. JAMA Cardiol. 3, 849–857 (2018).
Article PubMed PubMed Central Google Scholar
Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060–2069 (2021).
Article CAS PubMed Google Scholar
Brock, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 77, 1845–1855 (2021).
Ridker, P. M. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc. Res. 117, e138–e140 (2021).
Article CAS PubMed PubMed Central Google Scholar
Del Buono, M. G. et al. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on Interleukin-1. Eur. J. Clin. Invest. 54, e14110 (2024).
Broderick, L. & Hoffman, H. M. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat. Rev. Rheumatol. 18, 448–463 (2022).
Article CAS PubMed PubMed Central Google Scholar
Schiff, M. H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 59, 103–108 (2000).
Abbate, A. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670–2683 (2008).
Article CAS PubMed Google Scholar
Abbate, A. et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment–elevation myocardial infarction. J. Am. Heart Assoc. 9, e014941 (2020).
Article CAS PubMed PubMed Central Google Scholar
Abbate, A. et al. Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur. Heart J. Cardiovasc. Pharmacother. 8, 503–510 (2022).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
留言 (0)